Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EuroEyes International Eye Clinic's EBIT per Share for the
six
months ended in Dec. 2025 was HK$0.16.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was HK$0.35.
During the past 12 months, the average EBIT per Share Growth Rate of EuroEyes International Eye Clinic was 16.60% per year.
During the past 3 years, the average EBIT per Share Growth Rate was -3.80% per year.
During the past 5 years, the average EBIT per Share Growth Rate was -1.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for EuroEyes International Eye Clinic's EBIT per Share or its related term are showing as below:
HKSE:01846'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -18.5 Med: 5.3 Max: 51.6
Current: -3.8
During the past 10 years, the highest 3-Year average EBIT per Share Growth Rate of EuroEyes International Eye Clinic was 51.60% per year. The lowest was -18.50% per year. And the median was 5.30% per year.
HKSE:01846's 3-Year EBIT Growth Rate is ranked worse than 73.09% of 524
companies
in the Healthcare Providers & Services industry
Industry Median: 11.6
vs HKSE:01846: -3.80
EuroEyes International Eye Clinic (HKSE:01846) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
EuroEyes International Eye Clinic EBIT per Share Related Terms
EuroEyes International Eye Clinic EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EuroEyes International Eye Clinic EBIT per Share Chart
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$0.35
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EuroEyes International Eye Clinic (HKSE:01846) has a EBIT per Share of HK$0.35 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on EuroEyes International Eye Clinic and its competitors. According to the industry distribution chart, EuroEyes International Eye Clinic ranks #383 out of 524 companies in the Healthcare Providers & Services industry, placing it in the top 73.1%.
Is EuroEyes International Eye Clinic's EBIT per Share too high?
EuroEyes International Eye Clinic's current EBIT per Share is HK$0.35. Based on the distribution chart, EuroEyes International Eye Clinic ranks #383 out of 524 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, EuroEyes International Eye Clinic has a GF Score™ of 81/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does EuroEyes International Eye Clinic's EBIT per Share compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, EuroEyes International Eye Clinic ranks #383 out of 524 companies for EBIT per Share. This places EuroEyes International Eye Clinic in the lower half of its industry. The industry median EBIT per Share is 11.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Healthcare Providers & Services company?
The median EBIT per Share among Healthcare Providers & Services companies is 11.60, based on 524 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on EuroEyes International Eye Clinic and its competitors. For the Healthcare Providers & Services industry, the median EBIT per Share is 11.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. EuroEyes International Eye Clinic's current EBIT per Share is HK$0.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EuroEyes International Eye Clinic stock overvalued right now?
Based on GuruFocus' analysis, EuroEyes International Eye Clinic (HKSE:01846) is currently considered Significantly Undervalued. The stock's GF Value™ is HK$5.61, compared to a current price of HK$2.38 — trading 57.6% below its estimated fair value. The current EBIT per Share is HK$0.35. EuroEyes International Eye Clinic's overall GF Score™ is 81/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For EuroEyes International Eye Clinic (HKSE:01846), the current EBIT per Share is HK$0.35 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is EuroEyes International Eye Clinic (HKSE:01846) Overvalued in 2026?
Based on GuruFocus' analysis, EuroEyes International Eye Clinic stock appears to be undervalued.
The current stock price of HK$2.38 is trading 57.6% below its estimated GF Value™ of HK$5.61.
GuruFocus considers EuroEyes International Eye Clinic to be Significantly Undervalued.
Key valuation signals for HKSE:01846:
EBIT per Share: HK$0.35
GF Value™: HK$5.61 vs. price of HK$2.38 (57.6% below fair value)
No single metric tells the full story. See the HKSE:01846 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
EuroEyes International Eye Clinic Ltd is principally engaged in the provision of vision correction services in Germany, Denmark, the UK, the PRC including Hong Kong, and Switzerland. The Group is a high-end vision correction service provider in Germany, PRC, the UK, Denmark, and Switzerland. Its vision correction services include refractive laser surgery, phakic lens surgery (ICL), lens exchange surgery, and others including PRK/LASEK and ICRS implantation. Its revenue categories include provision of vision correction services generate maximum revenue, training services, sales of pharmaceutical products and others. The Group's five reportable segments are Germany generate maximum revenue, Denmark, UK, Chinese Mainland, and Switzerland.
81GF Score
Get the complete analysis for HKSE:01846
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:01846 has been successfully added to your 
